144 related articles for article (PubMed ID: 24091230)
1. Comparison of two treatment regimens with trilostane in dogs with pituitary-dependent hyperadrenocorticism.
Braun C; Boretti FS; Reusch CE; Sieber-Ruckstuhl NS
Schweiz Arch Tierheilkd; 2013 Oct; 155(10):551-8. PubMed ID: 24091230
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of baseline cortisol concentration to monitor efficacy of twice-daily administration of trilostane to dogs with pituitary-dependent hyperadrenocorticism: 22 cases (2008-2012).
Woolcock AD; Bugbee AC; Creevy KE
J Am Vet Med Assoc; 2016 Apr; 248(7):814-21. PubMed ID: 27003023
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
Cho KD; Kang JH; Chang D; Na KJ; Yang MP
J Vet Intern Med; 2013; 27(1):91-8. PubMed ID: 23167780
[TBL] [Abstract][Full Text] [Related]
4. Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
Arenas Bermejo C; Pérez Alenza D; García San José P; Llauet L; Pérez-López L; Melián C; C Feldman E
J Vet Intern Med; 2020 Jul; 34(4):1413-1422. PubMed ID: 32533623
[TBL] [Abstract][Full Text] [Related]
5. Clinical Relationship between Cholestatic Disease and Pituitary-Dependent Hyperadrenocorticism in Dogs: A Retrospective Case Series.
Kim KH; Han SM; Jeon KO; Kim HT; Li Q; Ryu MO; Song WJ; Park SC; Youn HY
J Vet Intern Med; 2017 Mar; 31(2):335-342. PubMed ID: 28064467
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
[TBL] [Abstract][Full Text] [Related]
7. Effects of trilostane on the pituitary-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism.
Galac S; Buijtels JJCWM; Mol JA; Kooistra HS
Vet J; 2010 Jan; 183(1):75-80. PubMed ID: 19042143
[TBL] [Abstract][Full Text] [Related]
8. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.
Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
Domest Anim Endocrinol; 2006 Jul; 31(1):63-75. PubMed ID: 16233969
[TBL] [Abstract][Full Text] [Related]
9. Update on the use of trilostane in dogs.
Lemetayer J; Blois S
Can Vet J; 2018 Apr; 59(4):397-407. PubMed ID: 29606727
[TBL] [Abstract][Full Text] [Related]
10. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
Braddock JA; Church DB; Robertson ID; Watson AD
Aust Vet J; 2003 Oct; 81(10):600-7. PubMed ID: 15080470
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of cortisol and cortisone in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
Vet Rec; 2008 Oct; 163(16):477-81. PubMed ID: 18931355
[TBL] [Abstract][Full Text] [Related]
12. Carbenoxolone Disodium Treatment for Canine Pituitary-Dependent Hyperadrenocorticism.
Teshima T; Matsumoto H; Okusa T; Uchiyama R; Koyama H
PLoS One; 2016; 11(11):e0166267. PubMed ID: 27824928
[TBL] [Abstract][Full Text] [Related]
13. Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs.
Feldman EC; Kass PH
J Vet Intern Med; 2012; 26(4):1078-80. PubMed ID: 22708554
[TBL] [Abstract][Full Text] [Related]
14. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Griebsch C; Lehnert C; Williams GJ; Failing K; Neiger R
J Vet Intern Med; 2014; 28(1):160-5. PubMed ID: 24341822
[TBL] [Abstract][Full Text] [Related]
15. A comparison of once and twice daily administration of trilostane to dogs with hyperadrenocorticism.
Augusto M; Burden A; Neiger R; Ramsey I
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2012; 40(6):415-24. PubMed ID: 23242222
[TBL] [Abstract][Full Text] [Related]
16. Cortisol Concentrations in Well-Regulated Dogs with Hyperadrenocorticism Treated with Trilostane.
Midence JN; Drobatz KJ; Hess RS
J Vet Intern Med; 2015; 29(6):1529-33. PubMed ID: 26374943
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism.
Cook AK; Bond KG
J Am Vet Med Assoc; 2010 Oct; 237(7):801-5. PubMed ID: 20919845
[TBL] [Abstract][Full Text] [Related]
18. Effect of trilostane and mitotane on aldosterone secretory reserve in dogs with pituitary-dependent hyperadrenocorticism.
Reid LE; Behrend EN; Martin LG; Kemppainen RJ; Ward CR; Lurye JC; Donovan TC; Lee HP
J Vet Intern Med; 2014; 28(2):443-50. PubMed ID: 24400747
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Vaughan MA; Feldman EC; Hoar BR; Nelson RW
J Am Vet Med Assoc; 2008 May; 232(9):1321-8. PubMed ID: 18447776
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of baseline cortisol, endogenous ACTH, and cortisol/ACTH ratio to monitor trilostane treatment in dogs with pituitary-dependent hypercortisolism.
Burkhardt WA; Boretti FS; Reusch CE; Sieber-Ruckstuhl NS
J Vet Intern Med; 2013; 27(4):919-23. PubMed ID: 23701195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]